EPISODE · Jul 31, 2024 · 20 MIN
CEO Doug Drysdale on Cybin's Novel Approach to Treat Psychiatric Disorders with High Unmet Need
from WTR Small-Cap Spotlight · host Water Tower Research
Send us Fan MailNovel Psychedelics drug developer Cybin's CEO Doug Drydale joins WTR's Tim Gerdman and Robert Sassoon to talk about the company's fast-track development into a late-stage clinical development company, and what differentiates Cybin from other drug developers in the psychedelics space. Drysdale discusses Cybin's plans and priorities for its development pipeline going forward and talks about the company's extensive IP real estate. He also shares his perspectives on the regulatory uncertainty currently surrounding Lykos's MDMA-AT and how Cybin is dealing with it to its benefit
What this episode covers
Send us Fan Mail Novel Psychedelics drug developer Cybin's CEO Doug Drydale joins WTR's Tim Gerdman and Robert Sassoon to talk about the company's fast-track development into a late-stage clinical development company, and what differentiates Cybin from other drug developers in the psychedelics space. Drysdale discusses Cybin's plans and priorities for its development pipeline going forward and talks about the company's extensive IP real estate. He also shares his perspectives on the regulator...
NOW PLAYING
CEO Doug Drysdale on Cybin's Novel Approach to Treat Psychiatric Disorders with High Unmet Need
No transcript for this episode yet
Similar Episodes
Jun 12, 2025 ·30m
Apr 22, 2025 ·32m
Apr 17, 2025 ·16m
Feb 27, 2025 ·0m
Dec 16, 2024 ·39m